Skip to main content
Top
Published in: Acta Diabetologica 4/2012

01-08-2012 | Original Article

Structural damage in diabetic nephropathy is associated with TNF-α system activity

Authors: José Manuel Fernández-Real, Joan Vendrell, Isabel García, Wifredo Ricart, Martí Vallès

Published in: Acta Diabetologica | Issue 4/2012

Login to get access

Abstract

In experimental animal studies, tumour necrosis factor-α (TNF-α) contributed to renal hypertrophy during diabetes, and antibodies against TNF-α have led to improved histological lesions in animals with nephrotoxicity and diabetic nephropathy. We aimed to evaluate TNF-α system activity in association with renal histology in patients with type 2 diabetes. This is a prospective, cross-sectional study of 22 patients with type 2 diabetes (16 men), 13 with microalbuminuria and 9 with normoalbuminuria. Plasma-soluble TNF-α receptor 1 and 2 (sTNFR1 and sTNFR2) concentrations were used as surrogates of TNF-α system activity. Glomerular filtration rate (GFR) was analysed using I125-Iodothalamine. Albumin excretion rate (AER) and a renal biopsy were performed in all subjects. AER did not associate significantly with mesangial expansion or interstitial fraction in these subjects (r < 0.12, P > 0.5). AER was also not associated with either sTNFR1 or sTNFR2 levels. However, after controlling for GFR, the correlation between AER and sTNFR1 became significant (r = 0.47, P = 0.03). sTNFR1 correlated with age (r = 0.65, P < 0.001), mesangial expansion (r = 0.59, P = 0.004) and interstitial fraction (r = 0.58, P = 0.005). After controlling for age, body mass index and blood pressure, the association of TNFR1 with mesangial expansion persisted significant. Circulating sTNFR2 concentrations were not significantly associated with histological changes. In summary, structural kidney damage in patients with type 2 diabetes is associated with TNF-α system activity and specifically with plasma sTNFR1 concentrations.
Literature
1.
go back to reference Parving HH, Osterby R, Anderson PW, Hsuch WA (1996) Diabetic nephropathy. In: Brenner BM (ed) The kidney. Saunders, Philadelphia, pp 1864–1922 Parving HH, Osterby R, Anderson PW, Hsuch WA (1996) Diabetic nephropathy. In: Brenner BM (ed) The kidney. Saunders, Philadelphia, pp 1864–1922
2.
go back to reference Hasegawa G, Nakano K, Sawada M et al (1991) Possible tole of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 40:1007–1012PubMedCrossRef Hasegawa G, Nakano K, Sawada M et al (1991) Possible tole of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 40:1007–1012PubMedCrossRef
3.
go back to reference Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A (1988) Cachectin/TNF and IL-1 induced by glucose modified proteins: role in normal tissue remodelling. Science 240:1546–1548PubMedCrossRef Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A (1988) Cachectin/TNF and IL-1 induced by glucose modified proteins: role in normal tissue remodelling. Science 240:1546–1548PubMedCrossRef
4.
go back to reference Baund L, Oudinet JP, Marcelle B et al (1989) Production of tumor necrosis factor by rat mesangial cells in response to bacterial lipopolysaccharide. Kidney Int 35:1111–1118CrossRef Baund L, Oudinet JP, Marcelle B et al (1989) Production of tumor necrosis factor by rat mesangial cells in response to bacterial lipopolysaccharide. Kidney Int 35:1111–1118CrossRef
5.
go back to reference Navarro JF, Mora C, Rivero A et al (1999) Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am J Kidney Dis 33:458–463PubMedCrossRef Navarro JF, Mora C, Rivero A et al (1999) Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am J Kidney Dis 33:458–463PubMedCrossRef
6.
go back to reference Ortiz A, González-Cuadrado S, Bustos C et al (1995) Tumor necrosis factor as a mediator of glomerular damage. J Nephrol 8:27–34 Ortiz A, González-Cuadrado S, Bustos C et al (1995) Tumor necrosis factor as a mediator of glomerular damage. J Nephrol 8:27–34
7.
go back to reference Ng DP, Fukushima M, Tai BC et al (2008) Reduced GFR and albuminuria in Chinese type 2 diabetes mellitus patients are both independently associated with activation of the TNF-alpha system. Diabetologia 51:2318–2324PubMedCrossRef Ng DP, Fukushima M, Tai BC et al (2008) Reduced GFR and albuminuria in Chinese type 2 diabetes mellitus patients are both independently associated with activation of the TNF-alpha system. Diabetologia 51:2318–2324PubMedCrossRef
8.
go back to reference Fernández-Real JM, Broch M, Ricart W et al (1998) Plasma levels of the soluble fraction of tumor necrosis factor receptor-2 and insulin resistance. Diabetes 47:1757–1762PubMedCrossRef Fernández-Real JM, Broch M, Ricart W et al (1998) Plasma levels of the soluble fraction of tumor necrosis factor receptor-2 and insulin resistance. Diabetes 47:1757–1762PubMedCrossRef
9.
go back to reference Adamska A, Nikolajuk A, Karczewska-Kupczewska M et al (2011) Relationships between serum adiponectin and soluble TNF-α receptors and glucose and lipid oxidation in lean and obese subjects. Acta Diabetol (Epub ahead of print) Adamska A, Nikolajuk A, Karczewska-Kupczewska M et al (2011) Relationships between serum adiponectin and soluble TNF-α receptors and glucose and lipid oxidation in lean and obese subjects. Acta Diabetol (Epub ahead of print)
10.
go back to reference Wu W, Wang M, Sun Z, Wang X, Miao J, Zheng Z (2011) The predictive value of TNF-alpha and IL-6 and the incidence of macrovascular complications in patients with type 2 diabetes. Acta Diabetol (Epub ahead of print) Wu W, Wang M, Sun Z, Wang X, Miao J, Zheng Z (2011) The predictive value of TNF-alpha and IL-6 and the incidence of macrovascular complications in patients with type 2 diabetes. Acta Diabetol (Epub ahead of print)
11.
go back to reference Blank SE, Johnson EC, Weeks DK, Wysham CH (2010) Circulating dendritic cell number and intracellular TNF-alpha production in women with type 2 diabetes. Acta Diabetol (Epub ahead of print) Blank SE, Johnson EC, Weeks DK, Wysham CH (2010) Circulating dendritic cell number and intracellular TNF-alpha production in women with type 2 diabetes. Acta Diabetol (Epub ahead of print)
12.
go back to reference Dogrul A, Gul H, Yesilyurt O, Ulas UH, Yildiz O (2011) Systemic and spinal administration of etanercept, a tumor necrosis factor alpha inhibitor, blocks tactile allodynia in diabetic mice. Acta Diabetol 48:135–142PubMedCrossRef Dogrul A, Gul H, Yesilyurt O, Ulas UH, Yildiz O (2011) Systemic and spinal administration of etanercept, a tumor necrosis factor alpha inhibitor, blocks tactile allodynia in diabetic mice. Acta Diabetol 48:135–142PubMedCrossRef
13.
go back to reference Pfeilschifter J, Pignat W, Vosbeck K, Märki F (1989) Interleukin 1 and tumor necrosis factor synergistically stimulate prostaglandin synthesis and phospholipase A2 release from rat mesangial cells. Biochem Biophys Res Commun 159:385–394PubMedCrossRef Pfeilschifter J, Pignat W, Vosbeck K, Märki F (1989) Interleukin 1 and tumor necrosis factor synergistically stimulate prostaglandin synthesis and phospholipase A2 release from rat mesangial cells. Biochem Biophys Res Commun 159:385–394PubMedCrossRef
14.
go back to reference Royall JA, Berkow RL, Beckman JS et al (1989) Tumor necrosis factor and interleukin 1 increase vascular endothelial permeability. Am J Physiol 257:L399–L410PubMed Royall JA, Berkow RL, Beckman JS et al (1989) Tumor necrosis factor and interleukin 1 increase vascular endothelial permeability. Am J Physiol 257:L399–L410PubMed
15.
go back to reference Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D (1992) Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 175:323–329PubMedCrossRef Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D (1992) Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 175:323–329PubMedCrossRef
16.
go back to reference Nelson RG, Bennett PH, Beck GJ et al (1996) Development and progression of renal disease in Pima Indians with non insulin dependent diabetes mellitus. N Engl J Med 335:1636–1642PubMedCrossRef Nelson RG, Bennett PH, Beck GJ et al (1996) Development and progression of renal disease in Pima Indians with non insulin dependent diabetes mellitus. N Engl J Med 335:1636–1642PubMedCrossRef
17.
go back to reference Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG (2009) Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 52:691–697PubMedCrossRef Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG (2009) Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 52:691–697PubMedCrossRef
18.
go back to reference DiPetrillo K, Coutermarsh B, Gesek FA (2003) Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. Am J Physiol Renal Physiol 284:F113–F121PubMed DiPetrillo K, Coutermarsh B, Gesek FA (2003) Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. Am J Physiol Renal Physiol 284:F113–F121PubMed
19.
go back to reference Smith CA, Farrah T, Goodwin RG (1994) The TNF receptor superfamily of cellular and viral proteins: activation, costimulation and death. Cell 76:959–962PubMedCrossRef Smith CA, Farrah T, Goodwin RG (1994) The TNF receptor superfamily of cellular and viral proteins: activation, costimulation and death. Cell 76:959–962PubMedCrossRef
20.
go back to reference Sheikh MS, Huang Y (2003) Death receptor activation complexes: it takes two to activate TNF receptor 1. Cell Cycle 2:550–552PubMed Sheikh MS, Huang Y (2003) Death receptor activation complexes: it takes two to activate TNF receptor 1. Cell Cycle 2:550–552PubMed
21.
go back to reference Hofmann MA, Schiekofer S, Isermann B et al (1999) Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-κB. Diabetologia 42:222–232PubMedCrossRef Hofmann MA, Schiekofer S, Isermann B et al (1999) Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-κB. Diabetologia 42:222–232PubMedCrossRef
22.
go back to reference Satriano J, Schlöndorff D (1994) Activation and attenuation of transcription factor NF-κB in mouse glomerular mesangial cells in response to tumor necrosis factor-α, immunoglobulin G and adenosine 3′ 5′-cyclic monophosphate. J Clin Invest 94:1629–1636PubMedCrossRef Satriano J, Schlöndorff D (1994) Activation and attenuation of transcription factor NF-κB in mouse glomerular mesangial cells in response to tumor necrosis factor-α, immunoglobulin G and adenosine 3′ 5′-cyclic monophosphate. J Clin Invest 94:1629–1636PubMedCrossRef
23.
go back to reference Hruby AW, Shirota K, Jothy S, Lowry RP (1991) Antiserum against tumor necrosis factor-alpha and a protease inhibitor reduce glomerular injury. Kidney Int 40:43–51PubMedCrossRef Hruby AW, Shirota K, Jothy S, Lowry RP (1991) Antiserum against tumor necrosis factor-alpha and a protease inhibitor reduce glomerular injury. Kidney Int 40:43–51PubMedCrossRef
24.
go back to reference Moriwaki Y, Inokuchi T, Yamamoto A et al (2007) Effect of TNF-alpha inhibition on urinary albumin excretion in experimental diabetic rats. Acta Diabetol 44:215–218PubMedCrossRef Moriwaki Y, Inokuchi T, Yamamoto A et al (2007) Effect of TNF-alpha inhibition on urinary albumin excretion in experimental diabetic rats. Acta Diabetol 44:215–218PubMedCrossRef
25.
go back to reference Menghini R, Menini S, Amoruso R et al (2009) Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice. Gastroenterology 136:663–672PubMedCrossRef Menghini R, Menini S, Amoruso R et al (2009) Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice. Gastroenterology 136:663–672PubMedCrossRef
26.
go back to reference Serino M, Menghini R, Fiorentino L et al (2007) Mice heterozygous for tumor necrosis factor-alpha converting enzyme are protected from obesity-induced insulin resistance and diabetes. Diabetes 56:2541–2546PubMedCrossRef Serino M, Menghini R, Fiorentino L et al (2007) Mice heterozygous for tumor necrosis factor-alpha converting enzyme are protected from obesity-induced insulin resistance and diabetes. Diabetes 56:2541–2546PubMedCrossRef
27.
go back to reference Guerrero-Romero F, Rodriguez-Moran M, Paniagua-Sierra JR et al (1995) Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. Clin Nephrol 43:116–121PubMed Guerrero-Romero F, Rodriguez-Moran M, Paniagua-Sierra JR et al (1995) Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. Clin Nephrol 43:116–121PubMed
Metadata
Title
Structural damage in diabetic nephropathy is associated with TNF-α system activity
Authors
José Manuel Fernández-Real
Joan Vendrell
Isabel García
Wifredo Ricart
Martí Vallès
Publication date
01-08-2012
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 4/2012
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-011-0349-y

Other articles of this Issue 4/2012

Acta Diabetologica 4/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.